is where I started more than 20 years ago as a young MedChem student in the group of Maurizio Botta.
A back to the future adventure has brought us today to this new paper on .
We have tried to teach these old dogs new tricks for the development of agents.

chemistry-europe.onlinelibrary

An interesting point on
“.... How do we truly define a today? ... Are making the “wrong” kinds of molecules?
Or have we entered a new era of drug modalities?
.... And just to prove chemists can continue to make the “right” kinds of molecules, here are some recent low Mw drug -
-       Tecfidera (Mw 144), approved 2013
-       Tavaborole (Mw 151), FDA approved 2014
-       Avibactam (Mw 265), FDA approved 2015
-       Benznidazole (Mw 260), FDA approved 2017
-       Migalastat (Mw 163), FDA approved 2018
 
How many novel small molecule drugs Mw<300 are yet to be discovered?”

linkedin.com/posts/trevor-bret

As additional Appendix to my , I would like to our recent efforts in the field of : we have developed compounds acting at the same time as and or depending on the specific functionalization of the same chemotype.

chemistry-europe.onlinelibrary
pubs.acs.org/doi/10.1021/acs.j

As appendix to my and catalyst for possible collaborations in the field, I would like to our recent effort in the modulation of the /#CCR6 axis to identify new for and other depending on the same axis.

sciencedirect.com/science/arti

-Time for a short -

I am a group leader in at the University of Parma. My lab combines & techniques to develop novel pharmacological tools to study different Chronic Diseases (, , , , ) and Infective Agents (, , , , ).
We are particularly interested in the development of inhibitors and open to new in .
(sooner or later) about the and

Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.